Navigation Links
Opportunities in Medical Technology

BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available

ARLINGTON, Va., May 5 /PRNewswire/ -- BioInformatics, LLC announces the release of its newest report, Capitalizing on New Opportunities for Stem Cell Products. Despite a sluggish economy and cuts being made to laboratory budgets, the market for stem cell research products is expected to increa...

NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds

New Collaboration with Leading Researchers having Clinical Experience with Antimicrobials that are Biological Basis for Aganocide Compounds EMERYVILLE, Calif., April 22 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY ), a mid-stage biopharmaceutical company developin...

National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities

DENVER, Sept. 10 /PRNewswire-USNewswire/ -- National Jewish Health and Roche Diagnostics Corporation have reached a strategic agreement to pursue opportunities in the growing field of molecular diagnostics. This partnership will combine National Jewish's expertise in clinical testing and care ...

Presentations at American College of Cardiology Meeting Highlight New Opportunities for HDL Therapy

Intravascular Ultrasound Demonstrates Utility in Evaluating Drug Efficacy; Dr. H. Bryan Brewer, Jr. Sees Enormous Potential for HDL Therapy PLEASANTON, CA, Mar 30, 2007 (MARKET WIRE via COMTEX News Network) -- Lipid Sciences, Inc. (NASDAQ: LIPD) Dr. H. Bryan Brewer, Jr., Chief Scientific Direct...

Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 9, 2007 - Neose Technologies, Inc. (NasdaqGM:NTEC) announced today that it will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference held at the Mandarin Oriental Hotel in New York City from July 10-12, 2007. The Company's presentation is...

Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

BLOOMFIELD, N.J., July 05, 2007 /PRNewswire/ -- Alfacell Corporation today announced that Lawrence A. Kenyon, executive vice president, chief financial officer and corporate secretary, will present an overview of the company's product development programs at 8 a.m. EDT on Thursday, July 12, 2007, ...

GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Jul 5, 2007 - GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that Geoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled to present on Wednesday, July 11, 2007 at 9:00 a.m. during the C.E. Unterberg, Towbin Emerging Growth Life Opportunities C...

Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, July 03, 2007 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd , a leading microRNA company, announced today that J. Michael French, Rosetta Genomics President, will present at CE Unterberg, Towbin Emerging Growth Opportunities Conference on Tuesday, ...

EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Jul 3, 2007 - EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) today announced that Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX, is scheduled to present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Tuesday, July 10, 2007 ...

Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

DURHAM, N.C.--(BUSINESS WIRE)--Jul 3, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Christy L. Shaffer, Ph.D., President and CEO, will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Wednesday, July 11, 2007 at 11:00 am ET in New York City...

Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference

MALVERN, Pa., June 28, 2007 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc. today announced that Mr. Armando Anido, Chief Executive Officer and President, and Mr. Jim Fickenscher, Chief Financial Officer, will participate in the 2007 CEUT Emerging Growth Opportunities Conference to be hel...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

...e focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products...

Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty-Plus Year Historic Relationship

...easing the representation of each institution on the other party's governing board; Providing a framework for identifying and cultivating joint opportunities for philanthropic development; and Identifying approaches to co-brand select clinical programs. Montefiore Medical Center ...

Economy is Driving Many Osteoporotic Women to Retire Later - But Their Ability to Work May Be Undermined by Sub-Optimal Management of Their Disease

... Founded in 1949, the American Business Women's Association's (ABWA) mission is to bring together businesswomen of diverse occupations and to provide opportunities for them to help themselves and others grow personally and professionally through leadership with education, networking support and national recogni...

FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents

...e focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

...ment of novel genetically modified animal models of human disease. ZFN technology will make the generation of such animals faster and will create new opportunities in species other than mice. "Until now, rat geneticists lacked a viable technique for 'knocking out,' or mutating, specific genes to understa...

Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease

...e focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products...

Mayo Clinic Proceedings: A Comprehensive Review of Addiction to Prescription Painkillers Among Patients and Physicians

...n Kharasch, M.D., Ph.D., Department of Anesthesiology, Washington University in St. Louis, authored the editorial "Contemporary Clinical Opioid Use: opportunities and Challenges." It summarizes the recent increased interest in this drug category. Opioid medications are chemicals that work by binding to spec...

Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease

...e focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products...

New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects

...-cancer strategies." The recent discovery that non-coding RNAs, called microRNAs (miRNAs), play a critical role in gene regulation provides new opportunities to discover RNAs that can control angiogenesis. The major aim of this project is to establish a technology platform for the development of (anti-cance...

Acura and King Receive FDA Complete Response Letter Regarding Acurox(R)

...uartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription ph...

AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain

...isposition to analgesic gaps due to infiltrated and dislodged IV catheters. Additionally, the complexity and programmability of IV PCA pumps introduce opportunities for medication errors, which in some instances may be fatal. About ARX-01 Sufentanil NanoTab PCA System ARX-01 is a novel drug/device combina...

King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use

...quartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription ph...

Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative

... urgent needs. After-hours urgent care and telephonic nurse advice tied to EHR. Direct access to specialists. Group visits enhance educational opportunities and build social support among patients with common health needs. Telephone visits and secure messaging with the care team (GHC aims to make 3...

ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases

...ipal investigators, clinical trial facilities, medical school research partnerships, manufacturing, commercialization, global licensing and partnering opportunities for therapy, diagnostics and drug metabolism testing. Relationships with medical research foundations, public institutes of health, and life sciences ...

Spherix Announces Positive Phase 2 Study Results

...ase, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to diff...

CoAxia, Inc. Announces $21.5M Series D Financing

...ng Partner at Sofinnova Partners commented: "Sofinnova is pleased to have led the Series D round for CoAxia. We have long been interested in treatment opportunities in ischemic stroke, given the very large, global, untreated population. We had been following CoAxia's progress for many years and we felt it was the ...

VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease

...a Special Protocol Assessment. The Company is currently exploring strategic opportunities for launching this final phase of development. "The current treatment app... compounds licensed from Roche; -- our ability to obtain strategic opportunities to partner and collaborate with large biotechnology or pharmaceutica...

Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week

...e focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products...

Chipscreen and HUYA Bioscience to Present Clinical Data on Novel HDAC Inhibitor at the 2009 ASCO Annual Meeting

...reen.com . HUYA Bioscience International is a leader in enabling and accelerating the global co-development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese academic and commercial biopharmaceutical organizations to enhance de...

Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research

...pinions and support, view video updates, contribute, and learn of ongoing initiatives and progress in the fight against cancer. The scope of donation opportunities on the SU2C website ranges from naming a star in honor of a loved one to web team challenges that encourage collaborative fundraising efforts by group...

New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)

...e focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products...

Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms

...e focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products...

Juvenile Diabetes Research Foundation to Honor Duane DeSisto of Insulet Corporation and Senator Edward M. Kennedy at 27th Annual Hearts & Heroes Gala

... to editors: The honoree and other guests will be available for photo opportunities from 5:00 PM to 6:00 PM during a pre-Gala reception the night of the event ... In addition, the honoree and event emcees will also be available for photo opportunities at 6:45 PM in the Grand Ballroom. For more information, contact Lauren Shi...

Spherix Reports First Quarter 2009 Earnings

...ase, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to diff...

Spherix Elects New Independent Director, and Elects Chairman of the Board

...ase, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to diff...

Logical Therapeutics Appoints Peter A. Lankau as CEO and Director

...his understanding of the commercially important, and value creating elements of drug development, will help propel Logical toward significant business opportunities in the future." Top Line Study Results Logical also announced the reporting of data from its double-blind, randomized, active comparator s...

Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers

...erapeutics ever developed. The valuable information from this study is also expected to support Cardium and TRC advancing into other important product opportunities including pressure ulcers, venous stasis ulcers, bone injury repair and potentially other advanced therapeutic applications." About Cardium ...

AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System

...sposition to analgesic gaps due to infiltrated and dislodged IV catheters. Additionally, the complexity and programmability of IV PCA pumps introduce opportunities for medication errors, which in some instances may be fatal. About ARX-01 Sufentanil NanoTab PCA S y stem ARX-01 is a novel drug/device com...

Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis

... conjunctivitis). As current therapies do not address the underlying chronic inflammation, they fail to treat such a disease effectively. Significant opportunities exist for novel products in the ocular allergy market. Fovea is now preparing pivotal trials for Prednisporin(TM) both in the USA and in Europe ...
Other Tags
(Date:11/6/2014)... deaths occur because of metastasis, yet progress in ... slow. , "It,s been particularly challenging to design ... research fellow in systems biology at Harvard Medical ... until after they,ve already metastasized." , Gujral and ... should help researchers better understand how metastasis begins. ...
(Date:11/6/2014)... 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics ... related diseases announced a research collaboration with the ... Oncology, Inc (OTC: CSBR). , "There are many ... but Champions Oncology,s TumorGraft technology is unique in ... regimen experimentally generating vast amounts of valuable data. ...
(Date:11/5/2014)... his career to understanding the Earth,s climate and ... As deputy director and regional climatologist for the ... Institute, Redmond has more than three decades of ... climate data to the general public. , At ... on December 15-19, 2014 the American Geophysical Union ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
(Date:11/26/2014)... The family foundation of Best Buy founder, ... Research Foundation (Meso Foundation), half of which will be ... Grant Program . The focus area of the Richard ... with organizations that can generate transformational results in education, ... founder and chairman emeritus of Best Buy Co., Inc., ...
(Date:11/26/2014)... 2014 Increasing incidence rate of ... regulations are expected to be prime pharmacovigilance market ... of acute and chronic ailments has resulted in ... development. Moreover, growing adverse drug reaction related hospitalization ... become the need of the hour in the ...
(Date:11/26/2014)... Francisco, CA (PRWEB) November 26, 2014 Gone ... hanker after cheap deals on Black Friday, which signifies the ... to clicking items into their shopping carts in the comfort ... crowds. , This Friday is going to be ... in a day, with an estimated $2.48 billion in revenue ...
(Date:11/26/2014)... Loffler Companies has been selected as a 2014 ... information and news publication for resellers of imaging technology, ... Loffler has earned this prestigious award and the seventh ... honor the best and the brightest in the imaging ... chosen for their innovative marketing and sales programs, community ...
(Date:11/26/2014)... 26, 2014 GI for Life announced ... reductions in prices of their popular nutritional supplements: ... D3 . Discounts of 40% will be offered ... for Life’s proprietary ColoVite supplement is a scientifically formulated ... colon health. One easy-to-take colon vitamin with ALL the ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:2014 Best Friday Deals Revealed by Top10InAction 2Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2
Other Contents